PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-15.05%
Both companies show negative ROE. Martin Whitman would check if the entire market segment is distressed.
-8.76%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
-10.90%
Both companies show negative ROCE. Martin Whitman would investigate if external factors hamper profitability.
-41.23%
Negative margin while GNPX has 0.00%. Joel Greenblatt would demand urgent cost or pricing measures.
-9904.39%
Negative operating margin while GNPX has 0.00%. Joel Greenblatt would demand urgent improvements in cost or revenue.
-8774.56%
Negative net margin while GNPX has 0.00%. Joel Greenblatt would check if uncompetitive pricing or bloated costs cause losses.